NASDAQ:CCXIChemoCentryx Stock Price, Forecast & News

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CCXI stock has increased by 44.4% and is now trading at $59.99. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ChemoCentryx.

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for ChemoCentryx.

ChemoCentryx Inc (NASDAQ:CCXI) issued its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.05. The biopharmaceutical company had revenue of $6.01 million for the quarter, compared to analysts' expectations of $8.90 million. ChemoCentryx had a negative return on equity of 100.55% and a negative net margin of 192.93%. View ChemoCentryx's earnings history.

8 brokers have issued twelve-month price objectives for ChemoCentryx's shares. Their forecasts range from $54.00 to $102.00. On average, they anticipate ChemoCentryx's stock price to reach $70.13 in the next twelve months. This suggests a possible upside of 16.9% from the stock's current price. View analysts' price targets for ChemoCentryx.

Press coverage about CCXI stock has been trending negative on Saturday, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ChemoCentryx earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutChemoCentryx.

ChemoCentryx saw a decrease in short interest in May. As of May 15th, there was short interest totaling 2,060,000 shares, a decrease of 18.3% from the April 30th total of 2,520,000 shares. Based on an average daily trading volume, of 627,400 shares, the days-to-cover ratio is presently 3.3 days. Approximately 4.7% of the company's stock are sold short. View ChemoCentryx's Current Options Chain.

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Dynavax Technologies (DVAX), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Arrowhead Pharmaceuticals (ARWR), Advanced Micro Devices (AMD), Opko Health (OPK), NVIDIA (NVDA) and Inovio Pharmaceuticals (INO).

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx's stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (6.75%), BlackRock Inc. (6.33%), Wasatch Advisors Inc. (1.94%), State Street Corp (1.74%), UBS Group AG (1.46%) and Pictet Asset Management Ltd. (1.23%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View institutional ownership trends for ChemoCentryx.

CCXI stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., BlackRock Inc., Acadian Asset Management LLC, Frontier Capital Management Co. LLC, Wasatch Advisors Inc., WINTON GROUP Ltd, Morgan Stanley, and Two Sigma Advisers LP. Company insiders that have sold ChemoCentryx company stock in the last year include Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, and Thomas J Schall. View insider buying and selling activity for ChemoCentryx.

CCXI stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Pictet Asset Management Ltd., Lord Abbett & CO. LLC, Emerald Advisers LLC, International Biotechnology Trust PLC, Canada Pension Plan Investment Board, Emerald Mutual Fund Advisers Trust, and Invesco Ltd.. View insider buying and selling activity for ChemoCentryx.

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CCXI stock can currently be purchased for approximately $59.99.

ChemoCentryx has a market capitalization of $3.71 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

The official website for ChemoCentryx is www.chemocentryx.com.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]